Axsome Therapeutics Inc (AXSM) Investment Analysis
1. Executive Summary
Axsome Therapeutics Inc. (AXSM) is a leading commercial-stage biopharmaceutical company that has strategically positioned itself as a primary disruptor within the central nervous system (CNS) therapeutic landscape.[1, 2] The company's operational philosophy centers on the development of novel therapies for highly prevalent and burdensome CNS conditions where existing standards of care remain insufficient or provide suboptimal safety profiles.[3, 4] Axsome’s portfolio currently comprises three primary FDA-approved products—Auvelity, Sunosi, and Symbravo—which target significant markets including major depressive disorder (MDD), Alzheimer’s disease agitation (ADA), excessive daytime sleepiness (EDS) associated with narcolepsy and obstructive sleep apnea (OSA), and the acute treatment of migraine.[5, 6, 7]
The company generates revenue predominantly through the direct commercialization of its product portfolio in the United States, utilizing a specialized internal sales and marketing infrastructure that has reached significant scale.[3, 8] As of the first quarter of 2026, total quarterly revenue reached $191.2 million, representing a robust 57% year-over-year expansion.[2, 5] Product sales constitute the vast majority of this top line (approximately $189.4 million), while a smaller segment of revenue is derived from international royalty and milestone payments, particularly from out-licensed territories for Sunosi.[8, 9] Geographically, the United States remains the core growth engine, though strategic partnerships—such as the licensing agreement with Pharmanovia for Sunosi in Europe and the MENA region—provide incremental high-margin royalty streams.[1, 8]
Axsome’s primary customer base includes a broad spectrum of healthcare providers (HCPs), specifically psychiatrists, neurologists, primary care physicians, and geriatric specialists.[6, 7] In addition to individual practitioners, the company has increasingly focused on institutional customers, including long-term care (LTC) facilities, which are critical for the distribution of its recently approved Alzheimer’s disease agitation treatment.[6] Patients and physicians choose Axsome's products over traditional alternatives primarily due to differentiated pharmacological profiles. For example, Auvelity provides a rapid-acting oral mechanism (NMDA receptor antagonism) that contrasts with the multi-week delay of traditional SSRIs/SNRIs, and it lacks the mortality-related black-box warnings associated with atypical antipsychotics often used off-label or indicated for Alzheimer’s agitation.[10, 11, 12]
| Product |
Core Indication(s) |
Primary Customer Segment |
Differentiation Factor |
| Auvelity |
MDD, Alzheimer's Agitation |
Psychiatrists, LTC Facilities |
Rapid onset, non-antipsychotic safety |
| Sunosi |
EDS in Narcolepsy/OSA |
Sleep Specialists, Neurologists |
Non-stimulant DNRI profile |
| Symbravo |
Acute Migraine |
Neurologists, Primary Care |
MoSEIC™ enhanced rapid absorption |
The strategic value of Axsome is anchored in its ability to utilize the 505(b)(2) regulatory pathway, which allows for the rapid development of differentiated products by leveraging known chemical entities with established safety records.[3] This methodology significantly reduces clinical risk and development costs while ensuring long-term intellectual property (IP) protection extending into the 2040s.[7, 13] With a peak sales guidance exceeding $8 billion for its flagship asset, Auvelity, Axsome is transitioning into a self-sustaining neuroscience powerhouse.[14]
CNS MARKET DISRUPTOR
2. Business Drivers & Strategic Overview
Core Product Details and Market Positioning
Axsome’s commercial engine is driven by a portfolio of three distinct medicines targeting high-volume CNS conditions. Each product is positioned to capture market share by offering a clinical profile that addresses the specific failures of previous generations of therapy.
Auvelity (Dextromethorphan HBr and Bupropion HCl):
Auvelity is the first and only rapid-acting oral NMDA receptor antagonist approved for major depressive disorder.[12, 15] It utilizes bupropion as a pharmacokinetic enhancer to increase the bioavailability of dextromethorphan, which would otherwise be rapidly metabolized.[15, 16] This combination creates a multimodal mechanism targeting NMDA and sigma-1 receptors, modulating neurotransmitters implicated in mood regulation.[17] Beyond MDD, the landmark FDA approval in April 2026 for agitation associated with Alzheimer’s disease (ADA) has exponentially increased the drug’s total addressable market (TAM).[10, 18] In clinical trials (ADVANCE-1 and ACCORD-2), Auvelity demonstrated a statistically significant reduction in agitation symptoms by week 5 and a 72% reduction in the risk of relapse compared to placebo.[17, 19] Economically, Axsome prices Auvelity at approximately $1,248 for a 30-day supply, maintaining price parity between the MDD and ADA indications to streamline market access.[18]
Sunosi (Solriamfetol):
Acquired from Jazz Pharmaceuticals in 2022, Sunosi is a dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) indicated for EDS in adults with narcolepsy or OSA.[1, 20] Strategically, Axsome is treating Sunosi as a "pipeline in a product".[2] The company is currently executing a massive lifecycle management program, with ongoing or planned Phase 3 trials in ADHD, binge eating disorder (BED), and shift work disorder (SWD).[20, 21] The BED trial (ENGAGE) is expected to yield topline results in the second half of 2026, representing a near-term catalyst for revenue diversification.[22]
Symbravo (AXS-07):
Launched in mid-2025, Symbravo is a combination of rizatriptan and meloxicam specifically formulated using Axsome’s MoSEIC™ (Molecular Solubility Enhanced Inclusion Complex) technology.[1, 3] This technology is designed to overcome the absorption limitations of traditional oral triptans, particularly during a migraine attack when gastric stasis can delay drug efficacy.[3] Symbravo’s value proposition is built on providing rapid, sustained pain relief with lower rates of headache recurrence compared to rizatriptan alone.[20, 23]
Moat Analysis: Intellectual Property and Regulatory Strategy
Axsome’s competitive moat is not merely therapeutic but structural, consisting of a rigorous intellectual property framework and a specialized regulatory approach.
- IP Fortress: The company maintains a global portfolio of over 600 issued patents.[1] Crucially, Axsome has successfully defended its flagship assets against generic challengers. Settlements with Teva Pharmaceuticals for Auvelity and Alkem Laboratories for Sunosi have secured exclusivity until 2038-2040, providing nearly two decades of protected monopoly cash flows.[20, 24]
- 505(b)(2) Efficiency: Axsome’s reliance on the 505(b)(2) pathway allows it to bypass early-stage discovery risks.[3] By using molecules with known safety profiles, the company focuses its capital on Phase 3 execution and commercialization. This results in an exceptionally high R&D-to-product-approval efficiency ratio compared to peers developing entirely new molecular entities (NMEs).
- Distribution and Sales Scale: With a 630-person sales force, Axsome has reached the "critical mass" required to compete with large cap pharma.[6, 7] This scale provides a distribution moat; once an HCP is onboarded for Auvelity in MDD, the incremental cost of promoting Auvelity for ADA or Sunosi for future indications is significantly lower than for a single-product company.
Total Addressable Market (TAM) Analysis
Management estimates the combined potential of its marketed and pipeline assets to exceed $18 billion in annual peak sales.[7]
| Indication |
Estimated Patient Population (US) |
Market Context / TAM Drivers |
| Major Depressive Disorder |
~21 Million Adults |
High SSRI failure rates; need for rapid onset [4, 12] |
| Alzheimer's Agitation |
~5-7 Million Patients |
76% experience agitation; few approved options [4, 15, 18] |
| Binge Eating Disorder |
~2.8 Million Adults |
Largest unmet need in eating disorders; ENGAGE trial 2H 2026 [7] |
| ADHD (Adult/Pediatric) |
~10 Million Patients |
Significant demand for non-stimulant alternatives [7] |
The most immediate growth engine is ADA, where the estimated 7 million Americans with Alzheimer's represent a multi-billion dollar opportunity.[4, 15] Analysts project that this indication alone could generate between $2.0 billion and $2.1 billion in peak sales.[11, 25]
Competitive Landscape and Positioning
Axsome is currently holding and gaining ground in its core segments through clear clinical differentiation.
- Versus Rexulti (Otsuka/Lundbeck): In the ADA market, Rexulti was the first to market but carries a black-box warning for mortality in elderly dementia patients.[10, 11] Auvelity’s label lacks this class-wide antipsychotic warning, creating a significant safety-based competitive advantage.[10, 19] Management has explicitly studied Rexulti’s launch to optimize their own strategy in the LTC and caregiver channels.[18]
- Versus SSRIs/SNRIs: In the $10B+ depression market, Auvelity's 1-week onset of action is a "game changer" compared to the 4-6 weeks required for traditional antidepressants.[12]
- Versus Stimulants: Sunosi’s DNRI profile positions it as a safer alternative to Schedule II stimulants, which are increasingly under regulatory scrutiny and prone to shortages.[20]
STRATEGIC MOAT EXPANSION
3. Financial Performance & Valuation
Latest Quarterly Financial Results (Q1 2026)
Axsome reported its Q1 2026 financial results on May 4, 2026, showcasing a period of intensive commercial investment and significant top-line growth.[2, 26] While revenue growth remained robust, the company missed analyst expectations on the bottom line due to front-loaded sales and marketing expenses related to the Auvelity ADA launch.
Key Financial Metrics - Q1 2026 (Ended March 31, 2026):
* Total Revenue: $191.2 million, up 57% year-over-year from $121.5 million in Q1 2025.[5, 9]
* Net Product Sales: $189.4 million, with Auvelity contributing $153.2 million (+59% YoY) and Sunosi contributing $33.9 million (+34% YoY).[5, 9]
* Earnings Per Share (EPS): A loss of $1.26 per share, significantly wider than the consensus estimate of a $0.83-$0.85 loss.[2, 27]
* Net Loss: $64.5 million, compared to a $59.4 million loss in the prior year.[2, 5]
* Operating Expenses: Totaled $254.6 million, with SG&A accounting for $185.0 million (+53% YoY) and R&D for $52.7 million (+18% YoY).[5, 7]
* Cash Position: $305.1 million in cash and equivalents as of March 31, 2026, down from $322.9 million at year-end 2025.[5, 28]
Performance Analysis and Management Commentary:
The earnings miss was primarily driven by the "step-function" increase in SG&A spending to support the Auvelity ADA launch.[29, 30] CFO Nick Pizzie noted that the company accelerated pre-launch activities, including hiring an additional sales reps to reach the 630-person count and launching a national direct-to-consumer (DTC) campaign.[6, 29] Despite the wider loss, management reiterated that their current cash balance is sufficient to reach cash flow positivity.[2] Importantly, product gross margins remain exceptionally high (over 90%), suggesting that as revenue scales, the incremental profitability will be significant.[13, 31]
Market Impact and Analyst Reaction:
Following the announcement, the stock initially reacted with volatility but ultimately surged over 10-11% as investors looked past the quarterly loss to the positive catalyst of the ADA approval and the $8 billion peak sales guidance.[2, 5, 13] Analyst price targets were broadly raised, with HC Wainwright increasing its target to $270 and Needham to $255.[27, 30, 32]
Valuation Drivers and Assumptions
Axsome’s valuation is inherently tied to its ability to transition from a high-burn commercial entity to a high-margin cash flow generator.
- Revenue Trajectory: The 5-year sales growth is expected to be driven by Auvelity’s ADA ramp-up and label expansions for Sunosi. Analysts estimate 2026 revenue of $1.004 billion, representing a significant "crossing of the chasm" for the company.[21] By 2029, consensus revenue estimates reach $2.7 billion.[4]
- Operating Leverage: The primary driver for valuation is the stabilization of SG&A. If the sales force remains at current levels (approx. 630-700 reps), every additional dollar of revenue will flow directly to the bottom line at a ~90% marginal rate.[13]
- Gross-to-Net (GTN) Realization: Currently, GTN discounts for Auvelity and Sunosi are in the low-to-mid 50% range.[2, 6] A key valuation variable is whether these discounts improve as the company gains more leverage with PBMs or if they widen due to competitive pricing.
- Capital Structure: Axsome utilizes a $570 million Blackstone loan facility.[33, 34] Maintaining covenant compliance and eventually refinancing this debt with cash flow will be a major valuation milestone.
Valuation Multiples Comparison:
| Metric |
Axsome (AXSM) |
Peer Average (Biotech) |
US Pharma Average |
| P/S Ratio (TTM) |
16.1x - 16.6x |
8.2x |
5.2x |
| EV/Revenue (Fwd) |
~11x |
7x |
4x |
Source: [13, 35, 36]
The premium valuation is justified by Axsome’s 60%+ revenue growth rate and its de-risked portfolio of approved assets with multi-decade IP protection.[7, 37]
INVEST-TO-DOMINATE EXECUTION
4. Risk Assessment & Macroeconomic Considerations
Company-Specific Execution and Commercial Risks
The central risk to the Axsome investment thesis is the potential for a "slow start" in the Alzheimer's disease agitation indication. Unlike MDD, ADA treatment is heavily concentrated in long-term care (LTC) and assisted living facilities.[6, 17] These institutional channels have complex formulary review cycles that can take 6-12 months.
- LTC Channel Barriers: If Axsome fails to secure broad LTC formulary access by the end of 2026, launch metrics may disappoint, leading to a share price pullback.[6, 30]
- Sales Force Efficiency: The company has doubled its sales force in a short period.[6, 38] Managing such rapid headcount growth without losing commercial focus or quality of physician engagement is a significant operational challenge.
- Pipeline Failure: While the commercial portfolio is approved, the valuation also prices in success for AXS-12 (Narcolepsy) and AXS-14 (Fibromyalgia). Any "binary" trial failures or regulatory rejections for these assets would remove significant future revenue contributors.[4, 37]
Competitive and Industry Structure Risks
- Incumbent Resurgence: While Rexulti has a black-box warning, Otsuka and Lundbeck have significantly larger resources and established relationships in the geriatric market.[11, 18] A concerted marketing effort or price concessions by incumbents could hinder Auvelity’s market share gains.
- Generic Erosion and Litigation: Although settlements are in place, the pharmaceutical industry is prone to sudden "Paragraph IV" challenges from generic firms looking to break patents earlier than agreed.[24, 39]
- PBM/Payer Power: The high concentration of power among three major PBMs in the US means Axsome is vulnerable to rebate pressure. If Auvelity is excluded from a major formulary or placed on a high-tier (expensive) copay, volume growth could be severely impacted.[6, 40]
Regulatory and Legal Risks
- Medicare Part D and the IRA: The Inflation Reduction Act (IRA) introduces drug price negotiations. While management estimates no impact until 2031, any changes to the Part D redesign in 2025-2026 could increase Axsome’s liability for patient costs in the "catastrophic" phase of coverage, impacting net revenue per patient.[6, 39]
- Labeling Changes: As products like Auvelity reach hundreds of thousands of patients, the emergence of rare safety signals could lead the FDA to mandate additional warnings, potentially removing the "clean label" advantage Axsome currently enjoys.[41]
Macroeconomic and Capital Allocation Risks
- Interest Rate Sensitivity: Axsome’s debt facility with Blackstone is tied to SOFR plus a 4.75% margin.[34] Sustained high interest rates increase interest expense and delay the path to net income positivity.
- Capital Market Volatility: If Axsome requires additional capital before reaching cash flow positivity, a "closed" or highly volatile biotech market could force them to raise equity at a depressed valuation, diluting existing shareholders.[4]
| Risk Category |
Severity |
Probability |
Early Warning Sign |
| ADA Commercial Miss |
High |
Moderate |
Sequential stall in ADA Rx in Q3/Q4 2026 |
| Generic Challenge |
Critical |
Low |
New ANDA filings from non-settled generics |
| Medicare Payer Pressure |
Moderate |
High |
Widening GTN discounts above 60% |
NAVIGATING LAUNCH COMPLEXITY
5. 5-Year Scenario Analysis
This scenario analysis projects Axsome’s valuation based on the successful commercialization of Auvelity and Sunosi expansions, as well as the approval of the broader pipeline.
Financial Assumptions and Inputs
- Current Share Price: $206.53 (as of early May 2026).[5, 42]
- Shares Outstanding: ~51.4 Million.[5, 43]
- Revenue CAGR (5-Year): Range of 15% to 55%.
- Exit Multiples: Applied to Year 5 revenue (P/S) or Earnings (P/E).
Scenario 1: Base Case (The $8B Peak Path)
In this scenario, Axsome successfully launches Auvelity for ADA in June 2026. The drug follows a steady adoption curve in both MDD and ADA, reaching $3.5 billion in annual sales by 2031. Sunosi expands into BED and SWD, and AXS-12/14 achieve approval by 2028.
- Revenue (Year 5): $3.5 Billion.
- Net Margin: 38% (Achieved through significant operating leverage as SG&A scales modestly).
- Share Count: 55.0 Million (Accounting for employee stock options and minor dilution).
- Exit Multiple: 7.5x P/S (Standard for high-margin, late-cycle commercial biotech).
- Implied Share Price: $477.27.
- 5-Year Total Return: ~131%.
- Annualized Return: ~18.2%.
Scenario 2: High Case (Blue Sky Neuroscience Dominance)
Auvelity becomes the clear standard of care for ADA, capturing 40%+ of the market due to its clean label. MDD sales exceed expectations as the rapid-onset profile leads to it becoming a "front-line" recommendation. Solriamfetol (Sunosi) ADHD results are positive, opening a $5B+ market.
- Revenue (Year 5): $6.2 Billion.
- Net Margin: 45% (Exceptional margins due to ultra-high gross margin profile).
- Share Count: 52.0 Million (Aggressive buybacks initiated in Year 4).
- Exit Multiple: 10x P/S (Reflecting premier growth status).
- Implied Share Price: $1,192.30.
- 5-Year Total Return: ~477%.
- Annualized Return: ~42.0%.
Scenario 3: Low Case (Competitive and Regulatory Headwinds)
The ADA launch is hindered by Rexulti's defensive pricing and slow LTC adoption. Sunosi expansion into ADHD fails in Phase 3. PBMs mandate high step-therapy for Auvelity, keeping MDD growth in the single digits. IRA pricing negotiations start early.
- Revenue (Year 5): $1.6 Billion.
- Net Margin: 15% (High rebates and sustained marketing spend).
- Share Count: 62.0 Million (Required secondary offerings to fund burn).
- Exit Multiple: 3x P/S (Compressed multiple due to growth slowdown).
- Implied Share Price: $77.42.
- 5-Year Total Return: -62.5%.
- Annualized Return: -17.9%.
Scenario Analysis Summary Table
| Scenario |
Revenue (Yr 5) |
Net Margin |
P/S Multiple |
Future Price |
Total Return |
Ann. Return |
Prob. |
| High |
$6.20 Billion |
45% |
10.0x |
$1,192.30 |
477.3% |
42.0% |
20% |
| Base |
$3.50 Billion |
38% |
7.5x |
$477.27 |
131.1% |
18.2% |
55% |
| Low |
$1.60 Billion |
15% |
3.0x |
$77.42 |
-62.5% |
-17.9% |
25% |
Probability-Weighted Expected Share Price: $520.31
ASYMMETRIC GROWTH POTENTIAL
6. Qualitative Scorecard
| Metric |
Score (1-10) |
Narrative Analysis |
| Management Alignment |
9 |
CEO Dr. Herriot Tabuteau holds a significant direct/indirect stake (over 14%), ensuring his interests are tied to long-term equity appreciation.[44, 45] Compensation is heavily weighted toward performance-based stock units.[46, 47] |
| Revenue Quality |
8 |
Highly durable revenue streams with gross margins above 90%.[31] The primary detractor is the heavy reliance on PBM rebates to maintain formulary access.[6] |
| Market Position |
9 |
Axsome is rapidly gaining share in depression and is the first-mover in the high-safety ADA segment.[10, 11] The company is outperforming industry peers in revenue growth.[13, 30] |
| Growth Outlook |
10 |
The combination of a massive ADA launch and a Phase 3 pipeline across ADHD, BED, and Narcolepsy provides a best-in-class growth profile.[4, 7] |
| Financial Health |
7 |
Adequate cash for the current plan, but the company is still in a loss-making investment phase.[5, 28] Debt-to-equity remains high during this commercial scale-up.[31, 48] |
| Business Viability |
9 |
Intellectual property extends to the 2040s for all core products.[7, 13] The 505(b)(2) strategy ensures a higher probability of regulatory success than traditional biotech.[3] |
| Capital Allocation |
8 |
Disciplined acquisition of Sunosi and efficient deployment of the internal pipeline. Management has avoided over-paying for early-stage assets.[1, 20] |
| Analyst Sentiment |
9 |
Consensus is strongly bullish with 24 out of 25 analysts rating the stock a Buy.[4, 49] Price targets are consistently revised upward following regulatory wins.[32, 48] |
| Profitability |
3 |
Currently loss-making with an EPS of -$1.26 in the latest quarter.[2] The "bridge to profitability" is clear but not yet realized.[2, 30] |
| Track Record |
9 |
A history of successful FDA approvals and meeting critical commercial milestones. The company has transformed from clinical-stage to $1B+ revenue run-rate.[1, 41] |
Blended Qualitative Score: 8.1 / 10.0
HIGH CONVICTION PLATFORM
7. Conclusion & Investment Thesis
The investment thesis for Axsome Therapeutics (AXSM) is anchored in its successful transition to a multi-product commercial enterprise with an unmatched growth trajectory in the CNS space. The April 30, 2026, FDA approval of Auvelity for Alzheimer’s disease agitation (ADA) represents a watershed moment that de-risks the company’s most significant revenue contributor.[10, 16] While the Q1 2026 earnings miss highlighted the high costs of commercial scaling, the underlying fundamentals—including 57% revenue growth and 90%+ gross margins—suggest a business model with immense latent operating leverage.[2, 5, 13, 31]
Investors should focus on the second half of 2026 as the critical test for the Auvelity ADA launch. Successful penetration into the long-term care (LTC) channel and stabilization of SG&A expenses will be the primary drivers of multiple expansion. Furthermore, the upcoming clinical readouts for Sunosi in binge eating disorder and the potential NDA filing for AXS-12 in narcolepsy provide a continuous catalyst stream that differentiates Axsome from one-product biotechs.[7, 20, 22] Despite risks associated with PBM rebate pressure and the broader macroeconomic environment, Axsome’s patent fortress and first-in-class product profiles position it as a premier asset for long-term neuroscience exposure.
NEUROSCIENCE GROWTH POWERHOUSE
8. Technical Analysis, Price Action & Short-Term Outlook
Technically, Axsome Therapeutics (AXSM) is exhibiting strong bullish momentum following the ADA approval. The stock is currently trading significantly above its 200-day simple moving average (SMA) of $177.03 and its 50-day SMA of $189.10.[42, 50] After gapping higher to a new 52-week high of $234.29 on the approval news, the stock has found support in the $220–$227 range.[5, 13] While the RSI of 70.97 suggests the stock is reaching overbought territory, the MACD (12, 26, 9) signal remains firmly in "buy" territory.[30, 50] The short-term outlook is cautiously optimistic, with potential for consolidation as the market digests the Q1 earnings miss before the next leg up driven by June 2026 launch metrics.
BULLISH TREND CONTINUING
- Axsome Therapeutics, Inc. SEC 10-K Report - TradingView, https://www.tradingview.com/news/tradingview:7eefed6ce47e3:0-axsome-therapeutics-inc-sec-10-k-report/
- Earnings call transcript: Axsome Therapeutics Q1 2026 misses forecasts - Investing.com, https://www.investing.com/news/transcripts/earnings-call-transcript-axsome-therapeutics-q1-2026-misses-forecasts-93CH-4656550
- 10-K - SEC.gov, https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm
- What's Driving Axsome Therapeutics' Recent Bull Run - Kavout, https://www.kavout.com/market-lens/what-s-driving-axsome-therapeutics-recent-bull-run
- Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - Stock Titan, https://www.stocktitan.net/news/AXSM/axsome-therapeutics-reports-first-quarter-2026-financial-results-and-zmgvv4b3rw4x.html
- Axsome (AXSM) Q1 2026 Earnings Call Transcript | The Motley Fool, https://www.fool.com/earnings/call-transcripts/2026/05/04/axsome-axsm-q1-2026-earnings-call-transcript/
- Axsome Q1 2026 slides: 57% revenue growth amid FDA approval milestone - Investing.com, https://www.investing.com/news/company-news/axsome-q1-2026-slides-57-revenue-growth-amid-fda-approval-milestone-93CH-4656646
- Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update, https://axsometherapeuticsinc.gcs-web.com/node/12721/pdf
- Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - BioSpace, https://www.biospace.com/press-releases/axsome-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update
- FDA Approves First Non-Antipsychotic Treatment for Agitation Associated With Alzheimer Disease | Pharmacy Times, https://www.pharmacytimes.com/view/fda-approves-first-non-antipsychotic-treatment-for-agitation-associated-with-alzheimer-disease
- Axsome Drug's FDA Approval Unlocks New Opportunity in Alzheimer's Agitation, https://medcitynews.com/2026/05/axsome-alzheimers-disease-agitation-auvelity-fda-approval-axsm/
- EX-99.1 - SEC.gov, https://www.sec.gov/Archives/edgar/data/1579428/000119312526197857/axsm-ex99_1.htm
- AXSM Stock Surges As FDA Clears Auvelity In Alzheimer's Agitation - Timothy Sykes, https://www.timothysykes.com/news/axsome-therapeutics-inc-axsm-news-2026_05_04/
- Axsome projects Auvelity peak sales of at least $8B following Alzheimer's agitation approval and June launch - Seeking Alpha, https://seekingalpha.com/news/4585079-axsome-projects-auvelity-peak-sales-of-at-least-8b-following-alzheimers-agitation-approval
- Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer's Disease Agitation - BioSpace, https://www.biospace.com/press-releases/axsome-therapeutics-announces-fda-acceptance-and-priority-review-of-supplemental-new-drug-application-for-axs-05-for-the-treatment-of-alzheimers-disease-agitation
- A Review of Data on AXS-05 for Alzheimer Disease Agitation in Advance of Next Week's PDUFA Date | Psychiatric Times, https://www.psychiatrictimes.com/view/a-review-of-data-on-axs-05-for-alzheimer-disease-agitation-in-advance-of-next-weeks-pdufa-date
- Axsome Therapeutics, Inc. (AXSM) Discusses Approval of AUVELITY for Agitation Associated With Dementia Due to Alzheimer's Disease Transcript | Seeking Alpha, https://seekingalpha.com/article/4897438-axsome-therapeutics-inc-axsm-discusses-approval-of-auvelity-for-agitation-associated-with
- Look out Rexulti, Axsome's Auvelity has its nod for Alzheimer's agitation - Fierce Pharma, https://www.fiercepharma.com/pharma/look-out-rexulti-here-comes-axsome-alzheimers-agitation-fda-nod-auvelity
- Axsome Therapeutics Wins FDA Nod for Auvelity in Alzheimer's Agitation, Launch Set for June - MarketBeat, https://www.marketbeat.com/instant-alerts/axsome-therapeutics-wins-fda-nod-for-auvelity-in-alzheimers-agitation-launch-set-for-june-2026-05-01/
- EX-99.1 - SEC.gov, https://www.sec.gov/Archives/edgar/data/1579428/000119312526062421/axsm-ex99_1.htm
- Axsome Therapeutics (NASDAQ:AXSM) Q1 Revenue Beat Misses Estimates as Launch Costs Surge - ChartMill, https://www.chartmill.com/news/AXSM/Chartmill-46831-Axsome-Therapeutics-NASDAQAXSM-Q1-Revenue-Beat-Misses-Estimates-as-Launch-Costs-Surge
- Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update, https://investingnews.com/axsome-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update/
- Axsome (AXSM) Q1 2025 Earnings Call Transcript | The Motley Fool, https://www.fool.com/earnings/call-transcripts/2026/05/04/axsome-axsm-q1-2025-earnings-call-transcript/
- $AXSM Patent Settlement - axsome therapeutics inc - stockinsights.ai, https://stockinsights.ai/us/AXSM/8-K/contract-awards-20250210-d74
- Axsome earnings on deck after Alzheimer's drug approval - Investing.com South Africa, https://za.investing.com/news/earnings/axsome-earnings-on-deck-after-alzheimers-drug-approval-93CH-4247723
- Axsome Therapeutics, Inc. (AXSM) Q1 2026 Earnings Call Transcript | Seeking Alpha, https://seekingalpha.com/article/4898000-axsome-therapeutics-inc-axsm-q1-2026-earnings-call-transcript
- Axsome Therapeutics (NASDAQ:AXSM) Posts Earnings Results, Misses Expectations By $0.41 EPS - MarketBeat, https://www.marketbeat.com/instant-alerts/axsome-therapeutics-nasdaqaxsm-posts-earnings-results-misses-expectations-by-041-eps-2026-05-04/
- Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - Stocktwits, https://api-gw-prd.stocktwits.com/earnings-api/v1/documents/a39edde8-b7a0-475b-b3b6-ede7954fd521/8-K.pdf
- Axsome Therapeutics Q1 Earnings Call Highlights - MarketBeat, https://www.marketbeat.com/instant-alerts/axsome-therapeutics-q1-earnings-call-highlights-2026-05-04/
- Axsome Therapeutics Inc Stock (AXSM) Moved Up by 10.20% on May 4: Facts Behind the Movement - TradingKey, https://www.tradingkey.com/news/market-movers/261853810-market-movers-axsm-20260504
- Axsome Therapeutics, Inc. (AXSM) - Revenue (Annual) - AlphaQuery, https://www.alphaquery.com/stock/AXSM/fundamentals/annual/revenue
- AXSM Maintained by HC Wainwright & Co. -- Price Target Raised to $270 - GuruFocus, https://www.gurufocus.com/news/8839369/axsm-maintained-by-hc-wainwright-co-price-target-raised-to-270
- Axsome (NASDAQ: AXSM) grows Q1 2026 revenue to $191M while still posting a net loss, https://www.stocktitan.net/sec-filings/AXSM/10-q-axsome-therapeutics-inc-quarterly-earnings-report-5c6536d400e6.html
- 8-K - SEC.gov, https://www.sec.gov/Archives/edgar/data/1579428/000095017025069785/axsm-20250508.htm
- Axsome Therapeutics (AXSM) Reports Strong Q1 2026 Revenue Growth - GuruFocus, https://www.gurufocus.com/news/8839927/axsome-therapeutics-axsm-reports-strong-q1-2026-revenue-growth
- Assessing Axsome Therapeutics (AXSM) Valuation After Recent Share Price Momentum, https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/assessing-axsome-therapeutics-axsm-valuation-after-recent-sh-1
- AXSM: Priority Review In Alzheimer's Agitation Will Drive Future ..., https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/kgv9s5z6-cns-pipeline-advancements-will-expand-global-reach-iwav/updates/11-analysts-have-raised-their-blended-price-targets-on-axsome-t
- AXSM: Major 2026 catalysts include Auvelity's PDUFA for Alzheimer's agitation and field force expansion - TradingView, https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3045566:0-axsm-major-2026-catalysts-include-auvelity-s-pdufa-for-alzheimer-s-agitation-and-field-force-expansion/
- Patent Expiration Dates: The Calendar Every Pharmaceutical Investor Watches, https://www.drugpatentwatch.com/blog/patent-expiration-dates-the-calendar-every-pharmaceutical-investor-watches/
- Auvelity Cost 2026: Average Price and More - Healthline, https://www.healthline.com/health/drugs/auvelity-cost
- Axsome Therapeutics (AXSM) Stock Forecast: Analyst Ratings, Predictions & Price Target 2026 - Public Investing, https://public.com/stocks/axsm/forecast-price-target
- AXSOME THERAPEUTICS INC (AXSM) Stock Price & Overview - ChartMill, https://www.chartmill.com/stock/quote/AXSM/profile
- Axsome Therapeutics Shares Outstanding 2014-2025 | AXSM | MacroTrends, https://www.macrotrends.net/stocks/charts/AXSM/axsome-therapeutics/shares-outstanding
- AXSM Insider Trading - Axsome Therapeutics, Inc. - Fintel, https://fintel.io/sn/us/axsm
- Who Owns Axsome Therapeutics Inc? AXSM Shareholders - Investing.com, https://www.investing.com/equities/axsome-therapeutics-inc-ownership
- Axsome Therapeutics (AXSM) CEO granted 24081 performance stock units tied to milestones, https://www.stocktitan.net/sec-filings/AXSM/form-4-axsome-therapeutics-inc-insider-trading-activity-81560cef81d6.html
- Axsome Therapeutics (NASDAQ: AXSM) COO granted 8669 PSUs - Stock Titan, https://www.stocktitan.net/sec-filings/AXSM/form-4-axsome-therapeutics-inc-insider-trading-activity-58ee9c949241.html
- Axsome Therapeutics (NASDAQ:AXSM) Reaches New 12-Month High Following Analyst Upgrade - MarketBeat, https://www.marketbeat.com/instant-alerts/axsome-therapeutics-nasdaqaxsm-reaches-new-12-month-high-following-analyst-upgrade-2026-05-04/
- Axsome Therapeutics Inc (AXSM) Stock Forecast & Price Target - Investing.com, https://www.investing.com/equities/axsome-therapeutics-inc-consensus-estimates
- AXSM Technical Analysis, RSI and Moving Averages - Investing.com, https://www.investing.com/equities/axsome-therapeutics-inc-technical